Your browser doesn't support javascript.
loading
NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.
Johnson, J P; Focken, Thilo; Khakh, Kuldip; Tari, Parisa Karimi; Dube, Celine; Goodchild, Samuel J; Andrez, Jean-Christophe; Bankar, Girish; Bogucki, David; Burford, Kristen; Chang, Elaine; Chowdhury, Sultan; Dean, Richard; de Boer, Gina; Decker, Shannon; Dehnhardt, Christoph; Feng, Mandy; Gong, Wei; Grimwood, Michael; Hasan, Abid; Hussainkhel, Angela; Jia, Qi; Lee, Stephanie; Li, Jenny; Lin, Sophia; Lindgren, Andrea; Lofstrand, Verner; Mezeyova, Janette; Namdari, Rostam; Nelkenbrecher, Karen; Shuart, Noah Gregory; Sojo, Luis; Sun, Shaoyi; Taron, Matthew; Waldbrook, Matthew; Weeratunge, Diana; Wesolowski, Steven; Williams, Aaron; Wilson, Michael; Xie, Zhiwei; Yoo, Rhena; Young, Clint; Zenova, Alla; Zhang, Wei; Cutts, Alison J; Sherrington, Robin P; Pimstone, Simon N; Winquist, Raymond; Cohen, Charles J; Empfield, James R.
Afiliación
  • Johnson JP; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Focken T; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Khakh K; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Tari PK; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Dube C; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Goodchild SJ; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Andrez JC; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Bankar G; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Bogucki D; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Burford K; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada.
  • Chang E; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Chowdhury S; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Dean R; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • de Boer G; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Decker S; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada.
  • Dehnhardt C; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Feng M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Gong W; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Grimwood M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Hasan A; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Hussainkhel A; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Jia Q; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Lee S; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Li J; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada.
  • Lin S; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Lindgren A; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Lofstrand V; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada.
  • Mezeyova J; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Namdari R; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Nelkenbrecher K; Translational Drug Development, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Shuart NG; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Sojo L; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Sun S; Compound Properties, Xenon Pharmaceuticals Inc, Burnaby BC, Canada.
  • Taron M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Waldbrook M; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Weeratunge D; In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Wesolowski S; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Williams A; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Wilson M; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Xie Z; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Yoo R; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Young C; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Zenova A; In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Zhang W; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Cutts AJ; Chemistry, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Sherrington RP; Scientific Affairs, Xenon Pharmaceuticals, Inc, Burnaby BC, Canada.
  • Pimstone SN; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Winquist R; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Cohen CJ; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada.
  • Empfield JR; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, Canada.
Elife ; 112022 03 02.
Article en En | MEDLINE | ID: mdl-35234610
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsia / Canal de Sodio Activado por Voltaje NAV1.6 Límite: Animals Idioma: En Revista: Elife Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsia / Canal de Sodio Activado por Voltaje NAV1.6 Límite: Animals Idioma: En Revista: Elife Año: 2022 Tipo del documento: Article País de afiliación: Canadá